Gencaro Data in Atrial FibrillationClinical data from BEST, a Phase 3 trial in 2,708 patients with advanced heart failure, indicate that Gencaro may have a potentially enhanced and pharmacogenetically-influenced effect in reducing and preventing atrial fibrillation. In that trial, patients in the Gencaro arm demonstrated a reduction in the risk of new onset atrial fibrillation time to event compared to patients in the placebo arm of 41% (atrial fibrillation measured as an adverse event/serious adverse event or as detected on surveillance ECGs, time to event analysis, p = 0.0004). In a 1,040 patient DNA substudy of BEST, Gencaro exhibited pharmacogenetic enhancement and differentiation for atrial fibrillation prevention in patients with a specific genotype (beta 1389 arginine homozygous (Arg/Arg) adrenergic receptor (AR); approximately 47% of the patients). These patients experienced a 74% (p = 0.0003) reduction in risk of atrial fibrillation versus no detectable reduction in patients who had alternative genotypes (beta 1389 Gly carriers; 53% of the patients). The Company believes this data supports the potential ability of Gencaro to prevent atrial fibrillation in patients who have the genotype the Company believes responds most favorably to Gencaro.
ARCA Biopharma Announces Planned Expansion Of Gencaro Development To Atrial Fibrillation
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts